PLUS1
233.61
-5.12 (-2.14%)
-5.12 (-2.14%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
Level 1 Starter
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Penumbra Inc | PEN | NYSE | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| -5.12 | -2.14% | 233.61 | 20:00:00 |
| Close Price | Low Price | High Price | Open Price | Previous Close |
|---|---|---|---|---|
| 233.61 | 233.06 | 238.20 | 238.20 | 238.73 |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 4,794 | 120,663 | $ 234.03 | $ 28,239,331 | 245,923 | 107.50 - 241.81 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:00:00 | 16,491 | $ 233.61 | USD |
Penumbra Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 8.44B | 36.11M | 28.43M | $ 547.41M | $ 8.59M | 1.35 | 802.60 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| 2.78M | $ - | 0.00% | -35.99k | 6.90% |
Penumbra News
| Date | Time | Source | News Article |
|---|---|---|---|
| 8/03/2020 | 16:17 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 8/03/2020 | 16:05 | PR Newswire (US) | Penumbra, Inc. Reports Second Quarter 2020 Financial Results |
| 7/29/2020 | 16:05 | PR Newswire (US) | Penumbra, Inc. to Present at the Canaccord Genuity 40th.. |
| 7/20/2020 | 16:05 | PR Newswire (US) | Penumbra, Inc. Schedules Second Quarter 2020 Earnings.. |
| 7/14/2020 | 09:00 | Business Wire | Penumbra Augments Vascular Franchise with Latest Indigo.. |
| 6/09/2020 | 16:35 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 6/08/2020 | 16:37 | Edgar (US Regulatory) | Confidential Treatment Order (ct Order) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PEN Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 232.86 | 241.81 | 228.63 | 235.08 | 205,208 | 0.75 | 0.32% |
| 1 Month | 189.23 | 241.81 | 189.125 | 221.13 | 255,691 | 44.38 | 23.45% |
| 3 Months | 177.53 | 241.81 | 161.11 | 193.33 | 242,371 | 56.08 | 31.59% |
| 6 Months | 190.07 | 241.81 | 121.80 | 176.64 | 293,699 | 43.54 | 22.91% |
| 1 Year | 149.12 | 241.81 | 107.50 | 163.20 | 372,715 | 84.49 | 56.66% |
| 3 Years | 87.80 | 241.81 | 81.50 | 145.44 | 326,119 | 145.81 | 166.07% |
| 5 Years | 40.00 | 241.81 | 35.315 | 122.13 | 279,522 | 193.61 | 484.03% |
Penumbra Description
| Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are primarily sold to hospitals and are developed for use by specialist physicians. The neurovascular product category contributes to the majority of revenue. Within the neurovascular business, the firm offers products for the neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. Penumbra generates the majority of its revenue in the United States. |
